Eye disorder monoclonal antibody biosimilar - Zydus CadilaAlternative Names: MAB 6
Latest Information Update: 07 Apr 2014
At a glance
- Originator Zydus Cadila
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Eye disorders
Most Recent Events
- 28 Feb 2014 Early research in Eye disorders in India (Parenteral)